BUENOS AIRES, Argentina, Aug. 28, 2012 /PRNewswire/ -- A complex and diverse set of forces such as government investments, consolidation of the middle class, and high disease burden will fortify Brazil's position as a top-rung market in the global healthcare industry. A mesh of socioeconomic and demographic trends create significant opportunities for local and multinational companies in both healthcare and non-healthcare sectors, and will stoke double-digit growth rates by 2015. One of the biggest gainers will be the pharmaceuticals and biotechnology sector, which is expected to be the sixth largest in the world in 2015.
New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Healthcare Landscape, Outlook, and Growth Opportunities in Brazil, finds that the market earned revenues of $32.50 billion in 2011 and estimates this to reach $52.30 billion in 2015.
If you are interested in more information on this research, please send an email to Francesca Valente, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, title, telephone number, company email address, company Web site, city, state and country.
The Sistema Unico de Saude (SUS), Brazil's unified health system, has significantly increased citizens' access to healthcare with its $176 billion budget from the Multiannual Plan.
"The current positive economic scenario and increase in formal employment in Brazil will drive healthcare spending and the expansion of private health insurance industry," said Frost & Sullivan Industry Analyst William Fujioka. "Additionally, the higher prevalence of obesity, diabetes, HIV/AIDS, and cancer will provide opportunities for various healthcare stakeholders."
While the swelling patient pool attracts investors, complex administrative processes hamper investment, procurement, an
|SOURCE Frost & Sullivan|
Copyright©2012 PR Newswire.
All rights reserved